Full Text View
Tabular View
No Study Results Posted
Related Studies
Medication Adherence in Older People With Psychosis
This study is ongoing, but not recruiting participants.
First Received: October 29, 2003   Last Updated: April 24, 2008   History of Changes
Sponsored by: National Institute of Mental Health (NIMH)
Information provided by: National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier: NCT00071604
  Purpose

This study will determine whether Medication Adherence Therapy (MAT) can improve medication adherence and lower the risk of rehospitalization in older patients with psychosis.


Condition Intervention
Psychotic Disorders
Schizophrenia
Behavioral: Medication Adherence Therapy
Behavioral: Friendly Support Group

MedlinePlus related topics: Psychotic Disorders Schizophrenia
U.S. FDA Resources
Study Type: Interventional
Study Design: Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Official Title: Medication Adherence in Older Psychotic People

Further study details as provided by National Institute of Mental Health (NIMH):

Estimated Enrollment: 240
Study Start Date: September 2002
Estimated Study Completion Date: May 2008
Detailed Description:

Psychoses are among the most common and serious psychiatric disorders. Currently, the most effective treatment for psychoses involves the use of antipsychotic or neuroleptic medications. Unfortunately, pharmacologic regimens often do not achieve their goals because of poor medication adherence.

Nonadherence to antipsychotic treatment is a considerable public health problem that leads to myriad clinical and economic burdens, including psychotic relapse, increased clinic and emergency room visits, and rehospitalization.

Participants in this study are randomly assigned to receive either MAT or supportive treatment for 12 weeks. MAT is given in 15 sessions and consists of motivational interviewing, education, and social skills and behavior modification. Individual MAT sessions are held in Weeks 1 and 12; small group sessions take place in Weeks 2 through 11. Three monthly booster group sessions begin in Week 16. Participants are assessed at baseline and at 3, 6, and 12 months. Medication adherence, psychopathology, quality of life, medication side effects, health beliefs, and functioning are assessed.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • DSM-IV criteria for schizophrenia or schizoaffective disorder
  • Outpatient status at the time of enrollment
  • Currently prescribed maintenance treatment with antipsychotic medication (typical or atypical, oral or depot)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00071604

Locations
United States, California
Division of Geriatric Psychiatry Center (University of California, San Diego)
San Diego, California, United States, 92161
Sponsors and Collaborators
Investigators
Principal Investigator: Jonathan Lacro, PharmD VA San Diego Healthcare System & University of California, San Diego
  More Information

Additional Information:
No publications provided

Study ID Numbers: R01 MH62849, DATR A4-GPS
Study First Received: October 29, 2003
Last Updated: April 24, 2008
ClinicalTrials.gov Identifier: NCT00071604     History of Changes
Health Authority: United States: Federal Government

Study placed in the following topic categories:
Schizophrenia
Mental Disorders
Psychotic Disorders
Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:
Schizophrenia
Mental Disorders
Psychotic Disorders
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on May 07, 2009